Bionano Genomics, Inc. (NASDAQ:BNGO) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Bionano Genomics, Inc. (NASDAQ:BNGO) have been assigned a consensus rating of “Hold” from the four research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $7.50.

Several equities analysts have recently commented on BNGO shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bionano Genomics in a research note on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target (up previously from $10.00) on shares of Bionano Genomics in a research note on Monday, August 18th. Finally, Wall Street Zen raised Bionano Genomics from a “sell” rating to a “hold” rating in a research note on Monday, August 25th.

Hedge Funds Weigh In On Bionano Genomics

A hedge fund recently bought a new stake in Bionano Genomics stock. Everstar Asset Management LLC bought a new position in shares of Bionano Genomics, Inc. (NASDAQ:BNGO) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 44,984 shares of the company’s stock, valued at approximately $126,000. Everstar Asset Management LLC owned approximately 1.45% of Bionano Genomics at the end of the most recent quarter. Institutional investors own 11.35% of the company’s stock.

Bionano Genomics Stock Performance

NASDAQ BNGO opened at $1.72 on Tuesday. The stock’s fifty day moving average is $2.49 and its two-hundred day moving average is $3.18. The firm has a market capitalization of $7.12 million, a P/E ratio of -0.08 and a beta of 2.13. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.41 and a current ratio of 1.76. Bionano Genomics has a fifty-two week low of $1.50 and a fifty-two week high of $22.80.

Bionano Genomics (NASDAQ:BNGO) last released its quarterly earnings data on Thursday, August 14th. The company reported ($1.99) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.69) by $0.70. Bionano Genomics had a negative return on equity of 129.41% and a negative net margin of 271.02%.The company had revenue of $6.73 million for the quarter, compared to analyst estimates of $6.90 million. Bionano Genomics has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.